La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Halozyme Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Halozyme Therapeutics..

Halozyme Therapeutics (NASDAQ:HALO) Azioni, Catena delle Opzioni

HALOZYME THERAPEUTICS INC

Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics Inc

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) rose sharply during Friday's session after the <a href="https://www.benzinga.com/quote/EVLV">company announced preliminary first-quarter financial results.</a>
The company said it expects revenue growth of 40%+ in the first quarter.
Evolv Technologies shares jumped 21% to $5.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) jumped 33.7% to $12.34 after the company reported better-than-expected quarterly EPS results.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 30.2% to $1.64. NWTN announced the appointment of Mr. Benjamin Zhai as Executive Director of the Board and Global Chief Executive Officer.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) rose 29% to $22.70 after a court decision ruled in favor of the company regarding patent infringement claims over Nuplazid.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) gained 24.7% to $1.3596.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 18.5% to $77.95 after Nvidia disclosed it added a stake in the company via a 13F filing equating to approximately 24.18 million shares. Additionally, JP Morgan and Needham raised their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) gained 18.5% to $6.64.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) rose 14.4% to $36.36.</li>
<li>Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) surged 10.3% to $13.45.</li>
<li>Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) rose 7.5% to $15.59. Vipshop will announce first quarter 2025 financial results on May 20.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7% to $430.00.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 6.8% to $261.17 after the company announced a partnership with Webull Pay to power crypto experiences. Additionally, Benchmark raised its price target on the stock from $252 to $301.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 5% to $51.35.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45462276/applied-materials-flowers-foods-and-3-stocks-to-watch-heading-into-friday">Applied Materials, Flowers Foods And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

News

Intraday Update

Markets

Movers

ACAD

ACHR

APLD

COIN

CRWV

EVLV

HALO

NWTN

QUBT

SMLR

VIPS

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Overweight to Equal-Weight and lowers the price target from $73 to $62.

Downgrades

Price Target

Analyst Ratings

Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 57.2% to $2.94 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock rose 42.98% to $1.58. The market value of their outstanding shares is at $59.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 40.9% to $1.03. The company's market cap stands at $53.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock increased by 16.2% to $4.41. The company's market cap stands at $255.5 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 15.92% to $64.0. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 15.15% to $1.9. The company's market cap stands at $95.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 95.5% to $0.02 during Tuesday's after-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 44.08% to $0.07. The company's market cap stands at $1.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 36.9% to $296.59. The company's market cap stands at $3.8 billion. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock fell 24.91% to $50.0. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock declined by 23.96% to $10.41. The market value of their outstanding shares is at $62.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) shares decreased by 20.39% to $0.82. The company's market cap stands at $54.6 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

ATPC

AXDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KDLY

LUCY

OMER

PLRZ

VANI

12 Health Care Stocks Moving In Tuesday's After-Market Session

WIIM

Halozyme Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Market Perform to Underperform and announced a price target of $47.

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday.
The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&amp;P 500 also rose, gaining, 0.86% to 5,894.52.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Tuesday.
In trading on Tuesday, health care stocks fell by 2.5%.
Top Headline
Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living.
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, compared to economists&#8217; expectations of 2.4% and the previous reading.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 165% to $14.01 after the company announced it presented studies on HCW9206.</li>
<li>Shares of Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) got a boost, surging 33% to $3.1749 after the company reported better-than-expected first-quarter sales results.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 116% to $1.6001 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) shares dropped 17% to $29.90 following first-quarter financial results.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 81% to $0.1345 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) was down, falling 26% to $49.26. Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and announced a $47 price target.</li>
</ul>
Commodities In commodity news, oil traded up 2.9% to $63.75 while gold traded up 0.8% at $3,253.80.
Silver traded up 1.6% to $33.130 on Tuesday, while copper rose 2.1% to $4.7180.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.12%, while Spain's IBEX 35 Index rose 0.83%. London's FTSE 100 fell 0.02%, Germany's DAX 40 gained 0.31% and France's CAC 40 gained 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Trading Ideas

AFMD

HCWB

LOBO

MVST

XENE

Crude Oil Gains 3%; US Inflation Eases In April

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELU

CNSP

HUMA

SGMO

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

Leerink Partners downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Market Perform to Underperform and announces $47 price target.

Leerink Partners Downgrades Halozyme Therapeutics to Underperform, Announces $47 Price Target

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an average annual return of 15.92%. Currently, Halozyme Therapeutics has a market capitalization of $8.38 billion. 
Buying $100 In HALO: If an investor had bought $100 of HALO stock 15 years ago, it would be worth $921.02 today based on a price of $68.02 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746801014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 25.4% to $189.28 during Wednesday's regular session. The company's market cap stands at $2.4 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock increased by 23.37% to $0.4. The company's market cap stands at $4.3 million. </li>
<li>Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) stock moved upwards by 20.66% to $11.47. The market value of their outstanding shares is at $5.6 billion. The company's, Q1 earnings came out today. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) shares moved upwards by 19.47% to $13.56. The market value of their outstanding shares is at $587.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock rose 18.02% to $2.03. The company's market cap stands at $9.6 million. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 17.77% to $69.94. The market value of their outstanding shares is at $8.6 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.6% to $0.09 during Wednesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock fell 41.43% to $0.8. The company's market cap stands at $2.2 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 36.46% to $4.62. The company's market cap stands at $425.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 29.61% to $1.07. The company's market cap stands at $2.8 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 26.03% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock decreased by 24.03% to $3.39. The market value of their outstanding shares is at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

ELAN

HEPA

KTTA

MYGN

PHIO

TOVX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance. Also, Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $60 to $65.

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Equal-Weight and raises the price target from $60 to $65.

Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $65

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance.

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) raises FY2025 Adj EPS guidance from $4.95-$5.35 to $5.30-$5.70 vs $5.00 analyst estimate. Raises FY2025 sales outlook from $1.15 billion-$1.23 billion to $1.20 billion-$1.28 billion vs $1.20 billion estimate.

Guidance

Halozyme Therapeutics Raises FY2025 Adj EPS Guidance from $4.95-$5.35 to $5.30-$5.70 vs $5.00 Est; Raises FY2025 Sales Guidance from $1.15B-$1.23B to $1.20B-$1.28B vs $1.20B Est

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) reported quarterly earnings of $1.11 per share which beat the analyst consensus estimate of $0.94 by 18.09 percent. This is a 40.51 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $264.86 million which beat the analyst consensus estimate of $230.18 million by 15.07 percent. This is a 35.22 percent increase over sales of $195.88 million the same period last year.

Earnings

Earnings Beats

Halozyme Therapeutics Q1 Adj. EPS $1.11 Beats $0.94 Estimate, Sales $264.86M Beat $230.18M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.96.
The announcement from Halozyme Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 0.22% drop in the share price the next day.
Here's a look at Halozyme Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.16</td>
<td>0.98</td>
<td>0.78</td>
<td>0.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.26</td>
<td>1.27</td>
<td>0.91</td>
<td>0.79</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>13.0%</td>
<td>4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746457366_0.png" alt="eps graph" />
<h3>Tracking Halozyme Therapeutics's Stock Performance</h3>
Shares of Halozyme Therapeutics were trading at $61.19 as of May 02. Over the last 52-week period, shares are up 47.71%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Views on Halozyme Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Halozyme Therapeutics.
Analysts have provided Halozyme Therapeutics with 5 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $69.4, suggesting a potential 13.42% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Roivant Sciences and Exact Sciences, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Roivant Sciences, with an average 1-year price target of $18.0, suggesting a potential 70.58% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Exact Sciences, with an average 1-year price target of $63.92, suggesting a potential 4.46% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Roivant Sciences and Exact Sciences, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halozyme Therapeutics</td>
<td>Buy</td>
<td>29.55%</td>
<td>$255.95M</td>
<td>33.56%</td>
</tr>
<tr>
<td>Roivant Sciences</td>
<td>Buy</td>
<td>-42.05%</td>
<td>$8.76M</td>
<td>3.28%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>10.86%</td>
<td>$500.55M</td>
<td>-4.22%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Halozyme Therapeutics ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has a lower Return on Equity compared to its peers.
<h3>Discovering Halozyme Therapeutics: A Closer Look</h3>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Halozyme Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Halozyme Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.55%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Halozyme Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 45.98%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Halozyme Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.55%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 4.14, Halozyme Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/HALO/earnings">To track all earnings releases for Halozyme Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Halozyme Therapeutics's Upcoming Earnings

Halozyme Announces argenx Received A Positive CHMP Opinion Recommending EC Approval Of VYVGART 1000mg Developed With VYVGART 1000mg For Chronic Inflammatory Demyelinating Polyneuropathy

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $69.4, a high estimate of $75.00, and a low estimate of $58.00. This current average has increased by 1.46% from the previous average price target of $68.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582501_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Halozyme Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $58.00&#x7C;$55.00 &#x7C; 
&#x7C;Robert Wasserman &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $72.00&#x7C;$70.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $70.00&#x7C;$70.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Halozyme Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Halozyme Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Halozyme Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Discovering Halozyme Therapeutics: A Closer Look</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Breaking Down Halozyme Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Halozyme Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 45.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Halozyme Therapeutics's ROA excels beyond industry benchmarks, reaching 6.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Halozyme Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 4.14. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $72 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 5 years by 7.21% on an annualized basis producing an average annual return of 19.93%. Currently, Halozyme Therapeutics has a market capitalization of $6.97 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 5 years ago, it would be worth $2,470.54 today based on a price of $56.45 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745332223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years

Press Releases

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Comments

Halozyme Therapeutics

Halozyme Therapeutics (HALO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO